Loading…
Loading…
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portf.
Public Employees Retirement System of Ohio purchased a new stake in Teleflex Incorporated (NYSE: TFX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 12,584 shares of the medical technology company's stock, valued at approximately $1,595,000. Several other institutional investors have also recently
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with a.
Bank of New York Mellon Corp purchased a new position in Teleflex Incorporated (NYSE: TFX) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 263,156 shares of the medical technology company's stock, valued at approximately $33,358,000. Bank of
TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.
TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.